The most common problems associated with treating dyslipidemia are identifying patients who need to be treated, determining how aggressively they should be treated, and then encouraging them to comply with prescribed therapy. In addition, the degree of cardioprotection afforded by current agents is often suboptimal. Decision Resources Group’s Unmet Needs in Dyslipidemia analysis provides quantitative insight into U.S. and European physician perceptions of the unmet needs associated with dyslipidemia treatment, the goals of treatment, and the key drivers of therapy uptake. We discuss the commercial opportunities and how emerging therapies can capitalize on these opportunities.
Related Reports
Dyslipidemia - Landscape & Forecast - Disease Landscape & Forecast
Dyslipidemia is a key modifiable risk factor for atherosclerotic cardiovascular disease (ASCVD). Current...
Dyslipidemia | Disease Landscape and Forecast | G7 | 2020
Dyslipidemia is a key modifiable risk factor for atherosclerotic cardiovascular disease (ASCVD). Current lipid-modifying therapies include statins, ezetimibe, fibrates, omega-3 fatty acid compounds...
Dyslipidemia - Epidemiology - Mature Markets
DRG Epidemiology’s coverage of dyslipidemia comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of dyslipidemia for each co...